CR20120213A - Métodos para el tratamiento del cáncer usando antagonistas de notch - Google Patents

Métodos para el tratamiento del cáncer usando antagonistas de notch

Info

Publication number
CR20120213A
CR20120213A CR20120213A CR20120213A CR20120213A CR 20120213 A CR20120213 A CR 20120213A CR 20120213 A CR20120213 A CR 20120213A CR 20120213 A CR20120213 A CR 20120213A CR 20120213 A CR20120213 A CR 20120213A
Authority
CR
Costa Rica
Prior art keywords
treatment
methods
cancer
notch
notch antagonists
Prior art date
Application number
CR20120213A
Other languages
English (en)
Inventor
Christian W Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR20120213A publication Critical patent/CR20120213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del cáncer en general y leucemia en particular, utilizando antagonistas de Notch1 y Notch3 solos o en combinación. También se proporcionan composiciones y métodos para el tratamiento y diagnóstico de tipos de cáncer asociados a Notch.
CR20120213A 2009-09-30 2012-04-26 Métodos para el tratamiento del cáncer usando antagonistas de notch CR20120213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
CR20120213A true CR20120213A (es) 2012-07-09

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120213A CR20120213A (es) 2009-09-30 2012-04-26 Métodos para el tratamiento del cáncer usando antagonistas de notch

Country Status (21)

Country Link
US (1) US9200071B2 (es)
EP (1) EP2483311B1 (es)
JP (3) JP6025563B2 (es)
KR (1) KR101782180B1 (es)
CN (1) CN102630229B (es)
AU (1) AU2010300747A1 (es)
BR (1) BR112012007252A2 (es)
CA (1) CA2775880A1 (es)
CL (1) CL2012000800A1 (es)
CO (1) CO6531430A2 (es)
CR (1) CR20120213A (es)
EC (1) ECSP12011858A (es)
ES (1) ES2580229T3 (es)
HK (1) HK1170505A1 (es)
IL (1) IL218662A0 (es)
MA (1) MA33973B1 (es)
MX (1) MX342250B (es)
PE (1) PE20120998A1 (es)
RU (1) RU2012117619A (es)
WO (1) WO2011041336A2 (es)
ZA (1) ZA201201984B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
PL2307459T3 (pl) 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
US9090690B2 (en) 2009-06-18 2015-07-28 Pfizer Inc. Anti Notch-1 antibodies
US9127060B2 (en) 2010-12-15 2015-09-08 Wyeth Llc Anti-Notch1 antibodies
TW201726746A (zh) 2012-11-07 2017-08-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
PL2935330T3 (pl) * 2012-12-19 2019-11-29 Aveo Pharmaceuticals Inc Przeciwciała przeciw notch3
WO2014159239A2 (en) * 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
CN105051215A (zh) * 2013-03-15 2015-11-11 昂考梅德药品有限公司 治疗胰腺癌的方法
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
TW201902515A (zh) 2014-02-12 2019-01-16 美商建南德克公司 抗jagged1抗體及使用方法
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
ES2931955T3 (es) 2016-04-29 2023-01-05 Aveo Pharmaceuticals Inc Anticuerpo anti-Notch3

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック， インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
AR063493A1 (es) 2006-10-19 2009-01-28 Genentech Inc Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
BRPI0719409A2 (pt) * 2006-12-18 2014-02-11 Genentch Inc "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo"
US8088617B2 (en) * 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
US20100062012A1 (en) 2007-03-05 2010-03-11 Ioannides Constantin G Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2307459T3 (pl) * 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
US9090690B2 (en) * 2009-06-18 2015-07-28 Pfizer Inc. Anti Notch-1 antibodies

Also Published As

Publication number Publication date
ES2580229T3 (es) 2016-08-22
BR112012007252A2 (pt) 2020-08-11
KR101782180B1 (ko) 2017-10-23
CN102630229A (zh) 2012-08-08
KR20120100952A (ko) 2012-09-12
US9200071B2 (en) 2015-12-01
EP2483311B1 (en) 2016-05-18
JP2015145362A (ja) 2015-08-13
JP2017014219A (ja) 2017-01-19
WO2011041336A2 (en) 2011-04-07
CO6531430A2 (es) 2012-09-28
CA2775880A1 (en) 2011-04-07
WO2011041336A3 (en) 2012-05-03
US20120328608A1 (en) 2012-12-27
ZA201201984B (en) 2013-05-29
MX2012003851A (es) 2012-05-08
CL2012000800A1 (es) 2012-08-31
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
PE20120998A1 (es) 2012-08-14
RU2012117619A (ru) 2013-11-10
MX342250B (es) 2016-09-22
JP6025563B2 (ja) 2016-11-16
HK1170505A1 (en) 2013-03-01
EP2483311A2 (en) 2012-08-08
JP2013506675A (ja) 2013-02-28
MA33973B1 (fr) 2013-02-01
IL218662A0 (en) 2012-05-31
ECSP12011858A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
CR20120213A (es) Métodos para el tratamiento del cáncer usando antagonistas de notch
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
PA8740901A1 (es) Compuestos organicos
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BR112015012987A2 (pt) composições compreendendo anticorpos anti-cd38 e lenalidomida
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
CO6480975A2 (es) Mimetico de smac
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
EA201001639A1 (ru) Композиции и способы их получения и применения
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CO6341625A2 (es) Derivados de indol como agentes anticáncer
EA201290243A1 (ru) Хиназолиновые соединения
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.